Skip to main content

Table 2 Patient characteristics

From: Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities

 

No anticoagulation

Heparin

Citrate

 

n = 13

n = 8

n = 21

P

Age, yrs

70 (34–84)

57 (23–81)

64 (32–84)

0.49

Sex, male

7 (54)

6 (75)

14 (75)

0.59

Weight, kg

70 (50–100)

74 (55–135)

78 (60–110)

0.41

Sepsis

5 (39)

5 (63)

8 (38)

0.46

APACHE II at ICU admission

28 (11–42)

22 (15–37)

25 (14–41)

0.47

SAPS II at ICU admission

75 (43–112)

47 (37–77)

52 (32–86)

0.002

Creatinine, μmol/L

249 (100–410)

420 (156–626)

326 (47–622)

0.01

Urea, mmol/L

21 (6–48)

32 (12–97)

21 (6–41)

0.25

Leukocytes, ×109/L

8 (1–17)

12 (7–20)

12 (1–26)

0.29

Platelets, ×109/L

65 (22–173)

167 (44–352)

118 (35–332)

0.03

Prescribed CVVH dose, mL/kg/h

22 (16–32)

22 (11–32)

23 (16–31)

0.68

  1. Median (and range) or number (percentage). APACHE II Acute Physiology and Chronic Health Evaluation II, ICU intensive care unit, SAPS II Simplified Acute Physiology Score II